# Novo Nordisk A/S share price today (Novo Nordisk A/S, NVO)

> Novo Nordisk A/S's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. NVO · Healthcare · Drug Manufacturers - General · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/nvo

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: $40.19 (−18.7% in a year)
- P/E: 10.3×, against its own history
- Revenue (Jun 2026): DKK 78.5 B (+2.1% on a year ago)
- Profit (Jun 2026): DKK 21.0 B (−20.8% on a year ago)
- Operating margin: 42.5% (−1.0 points on a year ago)
- ROE: 53%, FY25
- ROIC: 39.2%, against a 5.7% cost of capital: +33.5 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Novo Nordisk A/S share price today? Novo Nordisk A/S's share price was $40.19 at the close on 3 November 2026. It has been falling for 9 weeks. That is 8.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between $36 and $62, and at that close it sat 16% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 9 weeks running. Over the last 10 years the share price moved +47% while the S&P 500 moved +255%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Novo Nordisk A/S pay? Novo Nordisk A/S declared DKK 3.75 per local share for Jun 2026, and DKK 23.35 over the last four reported quarters. It reports in Danish kroner, and one US-listed share can stand for several local shares, so we do not set this against the dollar price or show a yield. ## Which stock lists is Novo Nordisk A/S on? Novo Nordisk A/S is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Novo Nordisk A/S profitable? Novo Nordisk A/S earned DKK 21.0 B of net profit in the Jun 2026 quarter, −20.8% on the same quarter a year earlier. Full-year FY25 profit was DKK 102 B. Over 4 years profit has grown 21.0% a year on average. That is 26.7% of the quarter's revenue. The same quarter a year earlier earned DKK 26.5 B. For the full year, FY25 profit was DKK 102 B (+1.4% on the year before). Why profit moved: revenue changed +2.1% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +3.8% and revenue +5.9%. Profit and revenue are moving at about the same pace. This company reports in Danish kroner, not US dollars, so the money charts are left out here. The figures in the text are in that currency (DKK); nothing is converted. ## How much revenue does Novo Nordisk A/S make, and is it growing? Novo Nordisk A/S reported DKK 78.5 B of revenue in the Jun 2026 quarter, +2.1% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 21.7% a year on average. The last full year, FY25, came in at DKK 309 B. The last four reported quarters add to DKK 329 B. FY25 revenue was DKK 309 B, +6.4% on the year before. Recent pace: the last four quarters grew +5.9% on average, against 21.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +5.6%, against +13.0% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +4.8%, against +13.8% a year (rolling over). This company reports in Danish kroner, not US dollars, so the money charts are left out here. The figures in the text are in that currency (DKK); nothing is converted. ## How much of its sales does Novo Nordisk A/S keep? Novo Nordisk A/S's operating margin was 42.5% in the Jun 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 5 years it has been between 42.1% and 47.8%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.0 percentage points on the year while gross margin changed −5.1 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Novo Nordisk A/S' profit turning into cash? Over the last 3 years, 122% of Novo Nordisk A/S's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in DKK 119 B of operating cash against DKK 102 B of profit. After DKK 60.1 B of spending on assets, DKK 59.0 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. This company reports in Danish kroner, not US dollars, so the money charts are left out here. The figures in the text are in that currency (DKK); nothing is converted. ## Where does Novo Nordisk A/S' cash go? Novo Nordisk A/S does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent DKK 133 B on assets over the last 3 years. Averaged over those years that is 14.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: DKK 133 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. This company reports in Danish kroner, not US dollars, so the money charts are left out here. The figures in the text are in that currency (DKK); nothing is converted. ## What is Novo Nordisk A/S' P/E ratio, and how does it compare with its own history? Novo Nordisk A/S's P/E is 10.3×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Novo Nordisk A/S business getting better or worse? Novo Nordisk A/S's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE falling at 51.2%; each line tells part of the story. This is based on 12 quarters of 3 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Novo Nordisk A/S earn on its capital? Novo Nordisk A/S earned a ROE of 53% in FY25. Its return on capital used (ROIC) is 33.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 33.1% net margin and 0.57× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 33.1% net margin × 0.57× asset turnover × 2.80× leverage (assets divided by equity) ≈ 52.8% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 39.2% − 5.7% = +33.5 percentage points. The 5.7% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 39.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 42.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Novo Nordisk A/S have too much debt? Novo Nordisk A/S has total debt of DKK 140 B against shareholder equity of DKK 221 B as of Jun 2026, so its debt is 0.63× its equity. Year by year, that ratio went from 0.38 in FY21 to 0.67 in FY25. Keep that borrowing in mind when reading the returns on this page. This company reports in Danish kroner, not US dollars, so the money charts are left out here. The figures in the text are in that currency (DKK); nothing is converted. ## What is the Novo Nordisk A/S shareholding pattern? We have no ownership or short-position figures for Novo Nordisk A/S, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 2.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Novo Nordisk A/S from balance-sheet trouble? For Novo Nordisk A/S, the Z-score is 4.21. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 4.21 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Novo Nordisk A/S rank in its industry? There is no score against its industry: Novo Nordisk A/S is not among the largest members shown in this industry comparison for Drug Manufacturers - General. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Novo Nordisk A/S compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Novo Nordisk A/S in size? Novo Nordisk A/S is the 9th largest of 17 Drug Manufacturers - General companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: AstraZeneca PLC, Amgen Inc. and Gilead Sciences, Inc. Just below it: Pfizer Inc., Bristol-Myers Squibb Company and Sanofi. ### Drug Manufacturers - General companies close in size

1. [AstraZeneca PLC](https://www.sectoralpha.in/us/stocks/azn) $282.2 billion
2. [Amgen Inc.](https://www.sectoralpha.in/us/stocks/amgn) $249.4 billion
3. [Gilead Sciences, Inc.](https://www.sectoralpha.in/us/stocks/gild) $207.7 billion
4. Novo Nordisk A/S $177.4 billion
5. [Pfizer Inc.](https://www.sectoralpha.in/us/stocks/pfe) $171 billion
6. [Bristol-Myers Squibb Company](https://www.sectoralpha.in/us/stocks/bmy) $126.1 billion
7. [Sanofi](https://www.sectoralpha.in/us/stocks/sny) $108.1 billion

[All 17 Drug Manufacturers - General companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-general#all-companies)

### Companies close in size in other industries

1. [Salesforce, Inc.](https://www.sectoralpha.in/us/stocks/crm) $186.1 billion · Software - Application
2. [Union Pacific Corporation](https://www.sectoralpha.in/us/stocks/unp) $182.4 billion · Railroads
3. Novo Nordisk A/S $180.7 billion
4. [Deere & Company](https://www.sectoralpha.in/us/stocks/de) $180 billion · Farm & Heavy Construction Machinery
5. [NextEra Energy, Inc.](https://www.sectoralpha.in/us/stocks/nee) $178.3 billion · Utilities - Regulated Electric

## What else do people ask about Novo Nordisk A/S? ### What is Novo Nordisk A/S's stock price today? Novo Nordisk A/S's stock price is $40.19, −18.7% over the past year. The whole company is worth $177 B on the market. In the last 52 weeks it traded between $36 to $62; today it is 16% of the way up from the low, 8.7% below its 200-day average (as of 3 November 2026). ### What were Novo Nordisk A/S's latest quarterly results? Novo Nordisk A/S reported revenue of DKK 78.5 B and net profit of DKK 21.0 B for the Jun 2026 quarter. Revenue rose 2.1% and profit fell 20.8% compared with a year earlier. The operating margin was 42.5%, 1.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Novo Nordisk A/S's market cap? Novo Nordisk A/S's market capitalisation is $177 B at a stock price of $40.19. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Novo Nordisk A/S performing? Novo Nordisk A/S's share price has been falling for 9 weeks. In its latest quarter, revenue rose 2.1% and profit fell 20.8% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 9 weeks running (as of 3 November 2026). ### Will Novo Nordisk A/S's stock price go up? This page does not forecast Novo Nordisk A/S's stock price. What it shows instead: the stock price is $40.19, and it has been falling for 9 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Novo Nordisk A/S in its business cycle? Novo Nordisk A/S's FY25 operating margin was 45.5%, against a 5-year range of 42.1% to 47.8%: the middle of its own range, neither a peak nor a low. The latest quarter was 42.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Novo Nordisk A/S story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Novo Nordisk A/S a stock worth studying right now? What the numbers show: Novo Nordisk A/S's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.